Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
431-02-010 / 431-02-010 ISMRM Abstract

Tumor Metabolism and pH Assessment by CEST-MRI for Prediction of Immune Activation Status following Radiotherarapy in LARC

Primary: Body - Metabolism
Secondary: Contrast Mechanisms - CEST / APT / NOE
431-02-010 · A Clearer View Within: Advances in Body Imaging · Tuesday, 12 May, 1:40 PM–3:16 PM · Roof Terrace
431-02-010 · A Clearer View Within: Advances in Body Imaging · Tuesday, 12 May, 1:40 PM–3:16 PM · Roof Terrace
Keywords: Radiotherapy Locally advanced rectal cancer Chemical exchange saturation transfer Neoadjuvant immunochemotherapy (NICT) Tumor Metabolism
Accepted
Ziwei Jin 1, Lan Zhang1, Na Hao1, Peng Sun2, Ning Zheng3,4, Xin Li1
1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan 430022, Hubei Province, China
2Institute of Research and Clinical Innovations, Neusoft Medical Systems Co. Ltd, Shenyang, China
3Philips Healthcare (Beijing), Beijing, China
4Clinical and Technical Support, Philips Healthcare (Beijing), Beijing, China
Presenting Author: Ziwei Jin

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(10):1139-67.
2. Smith FM, Cresswell K, Myint AS, Renehan AG. Is "watch-and-wait" after chemoradiotherapy safe in patients with rectal cancer? Bmj. 2018;363:k4472.
3. Shin J, Seo N, Baek SE, Son NH, Lim JS, Kim NK, et al. MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemoradiotherapy. Radiology. 2022;303(2):351-8.
4. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363-76.
5. Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566-76.
6. Papke DJ, Jr., Yurgelun MB, Noffsinger AE, Turner KO, Genta RM, Redston M. Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas. N Engl J Med. 2022;387(18):1714-6.
7. Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol. 2019;4(41).
8. Lin ZY, Zhang P, Chi P, Xiao Y, Xu XM, Zhang AM, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Ann Oncol. 2024;35(10):882-91.
9. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, et al. Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer-weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study. Radiol Imaging Cancer. 2021;3(5):e200155.
10. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000;143(1):79-87.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/431-02-010